Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade.
Lu
Hailing
H
Tumor Vaccine Group, Center for Translational Medicine in Women's Health, 815 Mercer Street, Room 220, Box 358050, University of Washington, Seattle, WA 98195, USA. hlu@u.washington.edu
Wagner
Wolfgang M
WM
Gad
Ekram
E
Yang
Yi
Y
Duan
Hangjun
H
Amon
Lynn M
LM
Van Denend
Nathaniel
N
Larson
Emily R
ER
Chang
Amy
A
Tufvesson
Helena
H
Disis
Mary L
ML
D000208:Acute Disease; D000287:Administration, Topical; D000634:Aminoquinolines / Q000378:metabolism / Q000627:therapeutic use; D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000473:pathology; D006131:Growth Inhibitors / Q000819:agonists / Q000378:metabolism / Q000627:therapeutic use; D000077271:Imiquimod; D018836:Inflammation Mediators / Q000378:metabolism / Q000502:physiology* / Q000627:therapeutic use; D016753:Interleukin-10 / Q000037:antagonists & inhibitors* / Q000097:blood; D008024:Ligands; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*; D008562:Membrane Glycoproteins / Q000819:agonists* / Q000378:metabolism / Q000627:therapeutic use; D051379:Mice; D008822:Mice, Transgenic; D009361:Neoplasm Invasiveness / Q000276:immunology / Q000473:pathology* / Q000517:prevention & control; D011897:Random Allocation; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics; D051199:Toll-Like Receptor 7 / Q000819:agonists* / Q000378:metabolism / Q000627:therapeutic use; D017211:Treatment Failure; D015854:Up-Regulation / Q000276:immunology
D000634:Aminoquinolines; D006131:Growth Inhibitors; D000077271:Imiquimod; D018836:Inflammation Mediators; D016753:Interleukin-10; D008024:Ligands; D008562:Membrane Glycoproteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D051199:Toll-Like Receptor 7; C477038:Tlr7 protein, mouse; C483804:Erbb2 protein, rat